Kenvue Inc. (KVUE) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is modestly constructive — consensus is a beatable bar on both organic sales and EPS given Q1's strong 18.5% EPS beat, but the bigger swing factor is whether organic sales growth can sustain momentum into Q2 amid a choppy consumer backdrop and no management guidance.

Heading into Q2 2026, the bar for KVUE is achievable but not low. Consensus expects net sales of ~$3.96B (+3.9% YoY) and adjusted EPS of ~$0.31 (+10.3% YoY), both of which represent a step-up from Q1's already-strong print where KVUE delivered $3.91B in revenue and $0.32 adjusted EPS — the latter 18.5% above the prior consensus of $0.27. Management's tone has been constructive but deliberately muted: CEO Kirk Perry called Q1 an 'encouraging start' and cited 'meaningful year-over-year improvement in gross margin, operating margin, and EPS,' while simultaneously declining to provide any forward guidance due to the pending Kimberly-Clark transaction. Estimate revisions have been essentially flat since the Q1 print — the Q2 2026 EPS consensus of ~$0.31 and FY 2026 EPS consensus of ~$1.18 are little changed from the post-Q1 baseline, suggesting the street has absorbed Q1's upside without aggressively raising the bar. The stock has rallied ~11% since the Q1 earnings date (May 7) to ~$19.67, outperforming XLP (+1.6%) and SPY (+5.2%), with the move driven by multiple re-rating as the KMB deal timeline solidifies rather than estimate revisions — the stock now trades near the analyst consensus price target of ~$19.33–$19.50, implying limited near-term upside. The key wildcard is organic sales trajectory in Self Care: Q1 saw a -2.3% organic decline in Self Care driven by a weak cold/flu season, and Q2 faces a tougher comparison in that segment; if seasonal incidences normalize and Skin Health & Beauty's Q1 momentum (+5.0% organic) carries through, KVUE could surprise to the upside on the top line.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a beatable bar on EPS given Q1's outsized beat, but organic sales growth is the bigger swing factor — the street expects ~2.5% organic growth in Q2 vs. Q1's +0.7%, a meaningful acceleration that requires Skin Health & Beauty to sustain momentum and Self Care to recover from cold/flu weakness.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Sources: Visible Alpha consensus and actuals data. Note: No forward guidance is being provided by management due to the pending Kimberly-Clark acquisition. Organic sales growth Q2 2026 consensus derived from VA organic impact(%) consensus estimate of ~2.47%. Q2 2025 organic sales actual was -4.19% (VA actuals).

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs: Net Sales & Adj. EPS)

Pattern: KVUE has beaten adj. EPS consensus in 6 of the last 8 quarters, with the two most recent quarters showing outsized beats (+18.5% in Q1 2026, +22.7% in Q4 2025); net sales beats are less consistent (4 beats, 4 misses over 8 quarters), with revenue misses concentrated in the organic sales decline period of mid-2025. The EPS beat pattern is durable and driven by cost discipline and productivity savings.

Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Management has provided no forward guidance since the Kimberly-Clark merger announcement (November 2, 2025) and will not do so until the deal closes. Tone has been constructively cautious — Perry's 'encouraging start' language in Q1 is the most positive signal available, but the absence of guidance creates an information vacuum that makes consensus estimates harder to anchor.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been essentially stable since the Q1 2026 print — the Q2 2026 EPS consensus is flat vs. the post-Q1 baseline, and FY 2026 EPS has ticked up only marginally. The absence of guidance means revisions are driven purely by the street's own modeling, and the flat trajectory suggests analysts are waiting for Q2 results before making meaningful adjustments.

Estimates are remarkably stable post-Q1 print, with virtually no revision in either direction across all key KPIs. This reflects two dynamics: (1) the absence of management guidance removes the primary catalyst for estimate revisions, and (2) the street appears to be treating Q1's strong beat as a one-time positive rather than a signal to structurally raise numbers. The flat revision trajectory is a mild positive for the setup — the bar has not been raised, leaving room for another beat if execution continues.

Source: Visible Alpha consensus and actuals data. As-of date baseline uses May 12, 2026 (approximately 5 trading days post Q1 earnings on May 7, 2026).

5. Stock Performance

Key Takeaway: KVUE has significantly outperformed both XLP (+1.6%) and SPY (+5.2%) since the Q1 2026 earnings date, rallying ~11% to ~$19.67 — the move is driven primarily by deal-timeline confidence (KMB merger) and multiple re-rating rather than estimate revisions, which have been flat. The stock now trades at or above the consensus price target of ~$19.33–$19.50, suggesting limited upside from here absent a meaningful earnings beat.

KVUE vs. XLP (Consumer Staples ETF) vs. S&P 500 (SPY) — Indexed to 100 at May 7, 2026 (Q1 2026 Earnings Date). KVUE: +11.0% | XLP: +1.6% | SPY: +5.2%. Source: Stock Price Data.

• KVUE +11.0% since May 7, 2026 (Q1 earnings date), closing at $19.67 on August 6, 2026 vs. $17.72 at the earnings date close.
• XLP (Consumer Staples ETF) +1.6% over the same period — KVUE outperformed the sector by ~940 bps.
• S&P 500 (SPY) +5.2% over the same period — KVUE outperformed the broad market by ~580 bps.
• Key events during the period: KMB Q2 earnings (Aug 4, 2026) confirmed deal integration planning is on track with 'good line of sight on synergies' and 'greater confidence in the $1.9B cost synergy target,' which likely supported KVUE's late-period rally. Peer earnings from PG, CL, CHD, CLX, and NWL (late July/early August) provided mixed read-throughs on consumer health demand.
• Valuation context: At ~$19.67, KVUE trades at ~16.6x NTM adj. EPS of ~$1.18, a discount to consumer staples peers but appropriate given the pending acquisition at $21.01/share (KMB deal price). The stock is effectively range-bound between current levels and the deal price, with the spread representing deal risk premium.

6. Peer Commentaries — Q2 2026 Read-Through

Key Takeaway: Peer commentary from Q2 2026 earnings (reported late July – early August 2026) paints a mixed but broadly constructive picture for KVUE: consumer health categories are resilient, gross margin expansion is achievable through productivity, and e-commerce is a growth driver — but North American retailer inventory reductions and a choppy consumer (especially lower-income) are headwinds that could weigh on KVUE's Self Care segment.

Note: All peer commentary below is from Q2 2026 earnings releases and calls (reported July 28 – August 4, 2026), which are read-throughs for KVUE's upcoming Q2 2026 print. No prior-quarter commentary is included.

Kimberly-Clark (KMB) — Q2 2026 Earnings Call (August 4, 2026)

Most relevant peer given pending acquisition. KMB's Q2 results were mixed: organic growth came in ~100 bps below expectations, driven by a China diaper business disruption in late June and an unanticipated North America trade inventory reduction concentrated in adult care. However, KMB still delivered its '10th consecutive quarter of solid volume plus mix performance' and held global weighted share.

• North America retailer destocking: KMB noted shipments in North America consumer categories lagged consumption by ~170 bps in Q2, with shipments down ~4% vs. consumption growth of +0.3%. For the first half, shipments lagged consumption by ~200 bps. This is a direct read-through for KVUE's Self Care and Essential Health segments, which have also faced trade inventory headwinds.
• Consumer pressure: KMB stated 'consumers are clearly under increased pressure,' with sentiment 'especially among lower income consumers, is weakening.' Category growth in North America moderated sequentially from 3.7% to 0.9% in Q2. This is a headwind for KVUE's volume-driven recovery.
• Tariff refund benefit: KMB received a $45M tariff refund in Q2 (roughly half of what it paid in North America), which drove better-than-expected operating profit and EPS. KVUE may also benefit from tariff refunds, though the magnitude is unclear.
• KVUE integration confidence: KMB management expressed 'greater confidence, maybe faster realization of the existing $1.9B cost synergy target' and noted 'the closer you look, the better it gets — there's more growth in these categories than we originally thought.' This is a positive signal for KVUE's standalone business quality.
• China disruption: KMB expects the China diaper disruption to be a 100 bps headwind for the full year (200 bps in H2). KVUE's Asia Pacific business has been recovering from prior destocking; any renewed China softness could be a headwind for KVUE's Essential Health and Skin Health segments.

Procter & Gamble (PG) — Q4 FY2026 Earnings Call (July 29, 2026)

PG delivered organic sales growth of ~1% for fiscal 2026, with volume up modestly and pricing adding 1 point. The company stabilized global market share and is growing share in China for the first time in 15 quarters. Key read-throughs for KVUE:

• North America sell-in vs. sell-out gap: PG noted a 3-point gap between sell-out (consumption +2%) and sell-in (-1%) in Q4, driven by the Amazon Prime Day shift to late June and retailer inventory reductions. This is a direct read-through for KVUE — if retailers are reducing inventory broadly, KVUE's Q2 shipments could lag consumption.
• Personal Health Care growing mid-singles: PG's Personal Health Care category (which includes Vicks, a direct competitor to KVUE's Self Care brands) grew mid-single digits in Q4. This suggests the broader OTC health category is healthy, which is a positive read-through for KVUE's Tylenol, Zyrtec, and Nicorette businesses.
• Skin & Personal Care growing mid-singles: PG's Skin and Personal Care category grew mid-single digits for the year, consistent with KVUE's Skin Health & Beauty segment's Q1 recovery (+5.0% organic). The category tailwind appears intact.
• Consumer bifurcation: PG noted its portfolio is 'skewed to the $100,000+ consumer' and sees 'discernment rather than inability to buy.' KVUE's brands (Tylenol, Neutrogena, Listerine) are similarly positioned in the mid-to-premium tier, suggesting limited private label risk.
• China recovery: PG is growing share in China for the first time in 15 quarters, with Greater China organic sales up 4% in Q4. This is a positive read-through for KVUE's Asia Pacific recovery narrative.
• Cost headwinds for FY2027: PG guided to ~$1B after-tax cost headwind in FY2027 driven by higher raw materials, energy, and transportation costs (assuming $90/bbl Brent). This is a forward-looking caution for KVUE's margin trajectory post-merger.

Colgate-Palmolive (CL) — Q2 2026 Earnings Call (July 31, 2026)

CL delivered strong Q2 results with organic sales growth led by emerging markets (up mid-single digits) and solid gross margin expansion. Key read-throughs for KVUE:

• North America category softness in May: CL noted a 'significant drop in North America categories in May' attributed to 'peak gasoline prices' and a 'commensurate impact on consumer confidence.' Categories 'rebounded in June' but remain 'below historical numbers.' This is a direct read-through for KVUE's Self Care segment, which is heavily North America-weighted.
• North America retailer inventory reductions: CL noted 'inventory reductions from key retailers' in North America, with shipments 'down three' while consumption was 'more or less at one.' This corroborates KMB's and PG's observations and is a headwind for KVUE's Q2 shipments.
• Oral Care strength: CL's Oral Care business in Latin America was 'up high, mid-single digits,' and China delivered 'consistent mid-single digit performance.' KVUE's Listerine (Oral Care within Essential Health) is a direct beneficiary of this category tailwind.
• Gross margin expansion achievable: CL raised its gross margin guidance to 'roughly flat for the year' (from 'down'), driven by execution on productivity and favorable mix. This is a positive read-through for KVUE's gross margin trajectory, which expanded 80 bps in Q1 2026.
• E-commerce as growth driver: CL highlighted e-commerce as a 'strong growth driver,' particularly in Asia. KVUE's Q1 2026 results also cited 'targeted actions to accelerate demand in the eCommerce channel' as a driver of Skin Health & Beauty growth.

Church & Dwight (CHD) — Q2 2026 Earnings Release (July 31, 2026)

CHD delivered a standout Q2 with organic sales growth of 5.8% (well above its 3% outlook), raising full-year guidance across all metrics. Key read-throughs for KVUE:

• Oral Care momentum: THERABREATH mouthwash and toothpaste were key drivers of CHD's domestic organic growth (+5.1%). THERABREATH competes directly with KVUE's Listerine in the mouthwash category. CHD's strong performance suggests the oral care category is healthy, but also signals intensifying competition for Listerine.
• Innovation driving share gains: CHD noted 'brands gained market share driven by innovation, distribution wins, and increased marketing investments,' with new product launches expected to account for ~half of organic growth. KVUE's Listerine global restage and new product launches (Listerine On-The-Go Sachets) are similarly positioned.
• E-commerce outperformance: CHD's global e-commerce grew 22.7% in Q2, with online sales representing 25.5% of total consumer sales. This is a positive read-through for KVUE's e-commerce acceleration strategy.
• Tariff refund benefit: CHD expects to receive ~$15M of Phase II tariff refund benefits in H2 2026. KVUE may similarly benefit from tariff refunds, providing a potential tailwind to margins.
• Raised full-year guidance: CHD raised organic sales growth outlook to 4%–5% (from 3%–4%) and adj. EPS growth to 6%–8% (from 5%–8%). This is the most bullish read-through in the peer group and suggests the consumer health/personal care category is in better shape than feared.

Clorox (CLX) — Q4 FY2026 Earnings Call (August 3, 2026)

CLX operated in a 'dynamic environment marked by heightened value-seeking behavior, increased competitive activity, inflationary pressures, and ongoing macroeconomic uncertainty.' Key read-throughs for KVUE:

• Elevated promotional environment: CLX expects a 'continued elevated promotional environment' in FY2027, aligning with pre-COVID levels. This is a headwind for KVUE's value realization (pricing) strategy, as more promotional activity across the category could pressure KVUE's price/mix contribution.
• Consumer wellness focus: CLX noted consumers 'continue to focus heavily on their wellness,' creating opportunities in health and hygiene. KVUE's Self Care and Essential Health segments are well-positioned to benefit from this trend.
• Inflation persistence: CLX guided to >$200M of inflation in FY2027 (more than double historical range), assuming $90/bbl Brent. This is a forward-looking caution for KVUE's cost structure, though KVUE's productivity program has been offsetting inflation effectively.
• Inventory levels in line: CLX noted inventory levels are 'largely in line with what we would expect' with 'no material inventory changes or pressures from retailers' — a more benign read than KMB and PG, though CLX's categories differ from KVUE's.

Newell Brands (NWL) — Q2 2026 Earnings Call (July 31, 2026)

NWL returned to year-over-year growth for the first time in over four years, with net sales +3% and core sales +2.3%. While NWL's categories (writing, baby, outdoor) differ from KVUE's, the macro read-throughs are relevant:

• Consumer income bifurcation: NWL noted the high-income consumer is driving mid-single digit growth in general merchandise, while the middle-income consumer is 'relatively flat to down low single digits' and the low-income consumer is 'stabilizing.' This is consistent with KVUE's positioning in the mid-to-premium tier of consumer health.
• Category environment better than feared: NWL noted categories declined ~1% in Q1 and were 'essentially flat' in Q2, better than the -2% decline assumed at the start of the year. For the full year, NWL now assumes -1% category decline. This is a mild positive for KVUE's category backdrop.
• Inflation headwinds doubling: NWL now expects ~$200M of inflationary impacts for 2026 (up from $100M initially), with $50M of that increase occurring since the last earnings call. This is a broader macro caution for KVUE's cost structure.
• Baby Care strength: NWL's baby segment delivered double-digit sales growth, with Graco U.S. POS up at a 'strong double-digit rate.' KVUE's Baby Care (within Essential Health) also grew across major regions in Q1 2026, and this read-through suggests the category remains healthy.

Peer Read-Through Summary Table

7. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is KMB's Q2 2026 earnings call (August 4) confirming accelerating confidence in the KVUE deal synergies and timeline — this is the primary driver of KVUE's stock outperformance and the key overhang on the print (deal close timing matters more than quarterly results).

• August 4, 2026 — KMB Q2 2026 Earnings: Kimberly-Clark confirmed 'good line of sight on synergies' and 'greater confidence, maybe faster realization of the existing $1.9B cost synergy target' for the KVUE acquisition. KMB also noted 'more growth in these categories than we originally thought when we did this deal.' Deal expected to close in Q4 2026. Implication: Positive for KVUE deal certainty; narrows the spread between current price (~$19.67) and deal price ($21.01).
• February 17, 2026 — 2026 Restructuring Initiative Announced: KVUE's Board approved a restructuring initiative expected to result in ~$250M of pre-tax charges in FY 2026, aimed at optimizing the operating model, transforming the supply chain, and reducing complexity. Implication: Charges will weigh on reported EPS but are non-cash/non-recurring; adjusted EPS should be unaffected. Watch for any update on restructuring progress in Q2 results.
• January 29, 2026 — Shareholder Votes Approved: Both KVUE and KMB shareholders voted overwhelmingly to approve the merger proposals. HSR waiting period expired February 4, 2026. Only foreign regulatory approvals remain outstanding. Implication: Deal risk is now primarily regulatory (foreign approvals) rather than shareholder or antitrust risk.
• May 7, 2026 — Q1 2026 Earnings Beat: KVUE reported Q1 2026 adj. EPS of $0.32 (vs. $0.27 consensus, +18.5% beat) and net sales of $3.909B (vs. $3.854B consensus, +1.4% beat). Adj. gross margin expanded 80 bps to 60.8%. CEO Perry called it an 'encouraging start' with 'net and organic sales growth for the second consecutive quarter.' Implication: Sets a high bar for Q2 on EPS but demonstrates the business is executing well ahead of the deal close.
• July 7, 2026 — Zacks Research Downgrade: Zacks Research downgraded KVUE from 'Strong Buy' to 'Hold.' Implication: Modest negative signal; consensus remains 'Hold' with 12 of 16 analysts at Hold and 3-4 at Buy. Average price target ~$19.33–$19.50, implying limited upside from current levels.
• June 15, 2026 — Weiss Ratings Upgrade: Weiss Ratings upgraded KVUE from 'Hold (C-)' to 'Hold (C).' Implication: Minor positive; reflects improving business fundamentals.
• April 7–15, 2026 — Multiple Price Target Cuts: UBS lowered PT from $19 to $18 (Neutral); Barclays lowered PT from $19 to $18 (Equal Weight); Citigroup lowered PT from $20 to $19 (Neutral). All cuts preceded Q1's strong beat. Implication: Post-Q1 beat, these targets are now below current trading levels, suggesting potential for upward revisions post-Q2 if results are strong.
• Macro: Middle East conflict and energy costs: Multiple peers (PG, CLX, KMB) cited Middle East-related energy and transportation cost inflation as a headwind, with PG assuming $90/bbl Brent for FY2027 guidance. Implication: KVUE's productivity program has been offsetting inflation effectively, but sustained energy cost pressure could compress margins in H2 2026 and beyond.
• Macro: Tariff refund environment: KMB ($45M), CHD ($15M), and NWL (~$126M) all received or expect tariff refunds in 2026. Implication: KVUE may also be eligible for tariff refunds that are not currently in consensus estimates, representing potential upside to Q2 margins.

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells by executives since Q1 earnings — the only notable transaction is General Counsel Matthew Orlando's open-market sale of ~$38.5K in shares on May 8, 2026 (one day after Q1 earnings). All other transactions are routine director deferred share unit awards or RSU vesting events, not discretionary trades. The absence of insider buying is unsurprising given the pending KMB acquisition at a fixed price.

Analysis: The only transaction of note is General Counsel Matthew Orlando's open-market sale of 38,491 shares on May 8, 2026 — one day after Q1 earnings — with no 10b5-1 plan indicated. The sale of his entire disclosed position is worth flagging, though the timing (post-earnings, post-beat) and the pending acquisition context (stock is range-bound between current price and $21.01 deal price) reduce the informational value. No executive has made an open-market purchase since the merger announcement, which is expected given the fixed deal price removes the upside optionality that typically motivates insider buying.

Source: SEC Form 4 filings via Insider Transaction Data.